Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination With Allogeneic Natural Killer Cells (AB-101) in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma

Next Previous
Trial Profile

A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination With Allogeneic Natural Killer Cells (AB-101) in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 101 Artiva Biotherapeutics (Primary) ; Acimtamig (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications Anaplastic large cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms LuminICE; LuminICE-203
  • Sponsors Affimed Therapeutics

Most Recent Events

  • 23 Apr 2025 According to an Affimed Therapeutics media release, company will present data from this study in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30-June 3, 2025 in Chicago, Illinois.
  • 10 Dec 2024 Initial results (As of 24 July 2024, n=10) assessing efficacy and safety of acimtamig in combination with cryopreserved off-the-shelf-cord blood derived NK cells (AB-101) in patients with R/R cHL, presented at the 66th American Society of Hematology Annual Meeting and Exposition.
  • 08 Dec 2024 According to an Affimed Therapeutics media release,company announced the presentation of data in a poster session at the 66th ASH Annual Meeting and ExpositioN describing this trial

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top